$SXTPW News
Last published 2w ago
- 2w agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal SyndromeGlobeNewswireWASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne diseases,
- 2w agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study PatientsGlobeNewswireAll five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR testsFour of five completed patients (80%) were negative on highly sensitive
- 2mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswire– On-demand company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET – – Management will be available for one-on-one investor meetings during the conference – WASHINGTON, Sept. 03, 2026
- 2mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Second Quarter 2026 ResultsGlobeNewswireWASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne diseases,
- 3mo agoSXTPSXTPW60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireWASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new
- 3mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026GlobeNewswireCompany plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- 60
- 4mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne DiseasesGlobeNewswireLicense expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme diseaseAgreement builds on
- 4mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe FatigueGlobeNewswireWASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines
- 5mo agoSXTPSXTPW60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical SupplementGlobeNewswireLicense allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency
- 5mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with BabesiosisGlobeNewswireEnrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestonesMinimum enrollment to support interim analysis expected as soon as early July 2026Randomized, double-blind,
- 6mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces First Quarter 2026 ResultsGlobeNewswireWASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported
- 7mo agoSXTPSXTPW60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel WebsiteGlobeNewswireTravelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platform WASHINGTON, April 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.
- 7mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces 2025 Annual ResultsGlobeNewswireFY 2025 net product revenues increased 65% to $1,005,000Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals,
- 9mo agoGDRXSXTPSXTPW60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx PartnershipGlobeNewswireGoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategyPartnership will improve
- 9mo agoSXTPSXTPW60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx UseGlobeNewswireWASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne
- 9mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria PreventionGlobeNewswirePartnership adds a travel-focused consumer telehealth platform to the ARAKODA® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the worldARAKODA is the only
- 10mo agoSXTPSXTPW60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split RatioGlobeNewswireWASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne
- 10mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC StateGlobeNewswireFurther validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support theory among specialists that Babesia infection may
- 11mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026GlobeNewswire6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaignAdditional clinical
- 11mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of MedicineGlobeNewswire90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet
- 12mo agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Third Quarter 2025 ResultsGlobeNewswireQ3 2025 net product revenue increased 223% year-over-year to $438 thousandGross profit/(loss) decreased from $24 thousand to $(100) thousand WASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals,
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis StudyGlobeNewswireBreakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)Results obtained using
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis StudyGlobeNewswireCompany engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company was split between ILADEF and GLA to recognize the winning nameB-FREE, a Phase
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireWASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireWASHINGTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisGlobeNewswire90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed by Q2 2026Site has clinical expertise in infectious disease trials and access to
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Second Quarter 2025 ResultsGlobeNewswireA now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model$1.97 million cash on hand, runway through March 31, 2026
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella BacteriaGlobeNewswireStudy will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell cultureBorrelia and Bartonella, together with Babesia, represent the "3Bs," pathogens
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public OfferingGlobeNewswireWASHINGTON, July 16, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the "Company" or "60 Degrees") (NASDAQ:SXTP, SXTPW)), a pharmaceutical company focused on developing new medicines for infectious
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public OfferingGlobeNewswireWASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the "Company" or "60 Degrees") (NASDAQ:SXTP, SXTPW)), a pharmaceutical company focused on developing new medicines for infectious
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 BillionGlobeNewswireNew Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progressTotal addressable market (TAM) for ARAKODA for Human Babesiosis is informed by results
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025GlobeNewswireData from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis WASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle FormatGlobeNewswireNew 8-count bottles now available through major retail pharmaciesARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June 04, 2025
- 1y agoSXTPSXTPWBabesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees PharmaceuticalsGlobeNewswire25,000 U.S. adults per year claim reimbursement for medical costs associated with babesiosis v. CDC estimates of 2,000A full 45 percent of persistent babesiosis cases include chronic fatigueHealthcare providers treating
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Announces First Quarter 2025 ResultsGlobeNewswireQ1 2024 net product revenues increased 55% year-over-year to $163.6 thousand.Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP;
- 1y agoSXTPSXTPWBabesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma SurveyGlobeNewswireIn a survey representative of the general U.S. adult population, 1.26 percent of respondents – equivalent to about 3 million people – reported having received a medical diagnosis of babesiosis during their life-time; CDC
- 1y agoSXTPSXTPWGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21GlobeNewswireWASHINGTON, April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow, infectious disease product development expert and chief executive officer of 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the
- 1y agoSXTPSXTPWSixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public HealthGlobeNewswireWASHINGTON, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Announces 2024 Annual ResultsGlobeNewswireFY 2024 net product revenues increased 140% to $607.6 thousand.FY 2024 gross profit increased $443.8 thousand from ($221 thousand) to $222.8 thousand. WASHINGTON, March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock SplitGlobeNewswireWASHINGTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced
- 1y agoSXTPSXTPWSixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®GlobeNewswireWASHINGTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), pharmaceutical company today announced that the United States Food and Drug
- 1y agoSXTPSXTPW60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWASHINGTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today
- 1y agoSXTPSXTPW60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWASHINGTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today
- 1y agoSXTPSXTPW60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWASHINGTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today
- 1y agoSXTPSXTPW60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWASHINGTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today
- 1y agoSXTPSXTPW60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisGlobeNewswireInvestigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings.Enrollment
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisGlobeNewswireCase reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed patients who have relapsing babesiosis and for whom prior
- 1y agoSXTPSXTPWSixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionGlobeNewswireWASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), pharmaceutical company, and Tufts Medical Center ("Tufts MC"), a leading academic
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's HospitalGlobeNewswireThe trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need.The clinical site is led by Brigham and Women's Hospital researchers Ann Woolley,
- 1y agoSXTPSXTPW60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsGlobeNewswireQ3 2024 sales revenue increased 164% year-over-year to $135 thousand.Sequential (quarter-over-quarter) net product revenue growth of 8.3%.Gross profit increased from ($20 thousand) to $24 thousand. WASHINGTON, Nov. 14,